Trial Profile

A Randomized, Open-Label, Active Controlled, Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Heparin; Low molecular weight heparins; Vitamin K antagonists
Indications Venous thromboembolism
Focus Adverse reactions; Therapeutic Use
Sponsors Bristol-Myers Squibb; Pfizer

10 Dec 2024 Results assessing the efficacy, safety, and pharmacokinetics/pharmacodynamics (PK/PD) of apixaban in pediatric patients (pts) requiring anticoagulation for the treatment of VTE, presented at the 66th American Society of Hematology Annual Meeting and Exposition
01 Jul 2024 This trial has been Completed in Austria, according to European Clinical Trials Database record.
07 Jun 2024 This trial has been Completed in Portugal, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com